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BOOK REVIEWS
Cancer Surveys-Maturation and Differentiation in
Leukaemias Vol. 1. No 2. M.F. GREAVES (Guest
Editor). Series Editor, L.M. FRANKS. Oxford.
Oxford University Press, 346 pp, £12.
If the standard of presentation in this second issue
of Cancer Surveys is maintained, the series will
comprise a valuable collection of useful reviews of
benefit to clinicians and scientists alike. In this
volume Dr. Greaves has solicited contributions
from eminent workers in the field of
leukaemogenesis, discussing topics ranging from
regulator-dependent growth of normal and
leukaemic cells to the role of karyotypic changes,
viral-promoter mediated changes in cell behaviour,
and aberrant differentiation programmes expressed
by leukaemic cells. In his introduction, Greaves
rightly points out that "the success of the newer-
(research)-developments will depend critically on a
synthesis of the ideas and methods used by different
groups." This is particularly true in the field of
normal h4emopoiesis and leukaemogenesis which in
the past >decade has witnessed an explosion in the
cell biological, biochemical and molecular biological
assay systems available for analyzing the cell
surface, intracellular and genomic changes
occurring during growth and differentiation. The
ultimate goal of course, is to understand the
regulatory networks concerned with control of
growth and development of stem- and lineage-
restricted cells and the perturbations of this
network during leukaemic transformation.
Beug, Hayman and Graf discuss their work with
avian retroviruses, the possible mechanism of
lineage-restricted transformation by viral "sub-
type", and introduce the oncogene concept. It may
be thought by some that chicken leukaemias are
not relevant to understanding the human disease!
Far from it. The cellular equivalent to the viral
oncogenes are not expressed only in birds, but in
human cells as well, and recent publications testify
to the possible importance of these genes and their
products in transformed human cells! This work is
discussed in more detail in a chapter by Varmus
who concludes that viruses which do not carry their
"own" oncogene may transform cells by activating
cellular oncogenes. They do this by acting as gene
promoters-affecting the transcriptional activity of
the region of DNA in which they have been
inserted.
There is also a chapter by Harrison on
differentiation of the murine erythroleukaemias.
(For newcomers to this field, I can recommend the
article as a thorough and competent review of this
complicated field. The article discusses the possible
mode of action, and target cell specificity of several
erythroleukaemia-inducing viruses and describes the
various ways in which the transformed cells can be
induced to express a differentiation programme.
Together with the article by Sachs-on the
development of myeloid leukaemia cells-this work
raises real hope for the future in exploiting the
differentiation ability of many leukaemias. In
leukaemic cells, growth and differentiation are
indeed uncoupled but the change is not irreversible.
In appropriate circumstances, differentiation (clonal
senescence) can be induced. In the article by
McCulloch et al. (the "godfather" of modern
experimental haematology) is described the concept
that leukaemic cell growth is determined by a
balance between self-renewal and determination,
but that as a consequence of determination there is
"a sequential expression of differentiation markers
in patterns dissimilar from those of normal
haemopoiesis." While several groups would
disagree with this model, the suggestion put
forward by McCulloch that the extent of deviation
from the normal pattern may be correlated with the
aggressiveness of the leukaemic cell population is
an interesting one and requires further
investigation. Finally, the article by Klein discusses
the karyotypic changes seen in some leukaemias
arising in mouse and man. In particular, both
translocations and trisomies may result in the
activation of oncogenes. When read in the context
of the work reported by Beug and Varmus, the
model is beautiful in its simplicity.
In conclusion, a readable book, well worth
buying.
T.M. Dexter,
Division of Experimental Haematology,
Paterson Laboratories,
Christie Hospital & Holt Radium Institute,
Manchester M20 9BX.
Assessment of Immune Status by the Leukocyte
Adherence Inhibition Test (Ed D.M.P. THOMSON).
London. Academic Press, 380 pp, 1982, £29.00.
Since first described the leuckocyte adherence
inhibition assay (LAI) has met with some criticism.
This is to be expected for any assay which claims to
have diagnostic significance for malignant disease,
particularly when introduced at a time (1972) when
confidence in the role of cell-mediated immunity
against human neoplasia was at a low ebb. Here
was an assay (based upon antigen-specific reduction
of adherence to plastic or glass surfaces of
leukocytes) which claimed to demonstrate organ-444 BOOK REVIEWS
related reactivity similar to that shown in
cytotoxicity assays the subject of much criticism at
that time.
The acceptance of the assay was not helped by
the fact that three assays were identified
(haemocytometer, tube and microplate) which not
only revealed different patterns of reactivity in
respect of correlation with the course of disease but
also in the nature of responsive cells and the
mechanism of reactivity. Each required a high level
of manual dexterity. The validity of the assay has,
however, been confirmed subsequently in elegant
studies using model antigens in both animal and
human systems (particularly by Powell and
associates) and this test should certainly rank with
the leukocyte migration inhibition assay with which
it has some similarities as a measure of immune
function.
This volume brings together the collected
experience of the several groups that have
successfully used LAI in its various forms and
identifies the methodological advances, such as
image analysis, and the difficulties of the test.
Large sections of the work deal with the
mechanisms of the different assays. Its aim is to
provide easy access to the information now
available in this area as well as a thorough
description of the technical aspects of the tests. To
be fair, much of the information has already been
published in the Cancer Research Monograph
reporting the 1978 Buffalo workshop on this assay.
Those familiar with the area will find little new
data on LAI (except in the paper by Thomson) and
a consideration of the role in rheumatoid arthritis.
The papers presented here largely retread well-worn
ground. It is significant that the experience of a
number of groups with less convincing data on the
applicability of LAI to investigations of immune
reactivity in malignant disease are not only missing
but not even mentioned!
Those committed to the use of LAI will find here
a useful compendium of the work of others in the
f'ield. As a review of the state of the art it succeeds
admirably. A critical document of the position of
LAI in cancer diagnosis it is not. If you have £30
to spend, keep it in your pocket and consult Cancer
Research, 39, 551-662 (1979). One may ask what
purpose a book like this, at such a price, has, given
the economic constraints now being placed on
library budgets and cancer research in general.
B.M. Vose,
Immunology Section,
Biosciences I,
ICI Pharmaceuticals Division,
Alderly Park, Cheshire.
Human Cancer Markers (Eds. S. SELL. and B.
WAHREN). Chichester. John Wiley & Sons Ltd, 428
pp, 1982, £42.95
The interset in cancer markers continues both in
the search for new markers as well as the growing
use of those markers that have passed from the
preliminary stage to commercial production. The
anchor topics such as markers in breast, bowel and
lung cancer each receive a chapter in this well
constructed volume. The authors explore and
explain the use and limitations of the markers in
current use in many hospitals, carcinoembryonic
antigen, alpha fetoprotein and a variety of
hormones that can identify tumours of the
endocrine system, as well as those tumours where
there is an inappropriate production of hormones.
The book, which is a companion to Dr. Sell's
Cancer Markers (Humana Press, Clifton, N.J. 1980)
is presented in series of 15 site-orientated chapters,
and a general overview of monoclonal antibodies.
The authors vary according to the chapters. A
personal viewpoint is expressed in several chapters
by well known contributors to their area of
research, S. Sell on the liver, J. Hobbs on the
pancreas, M. Seppala on the gynaecological cancers
to name a few, others write in pairs T.M.
Edgington teams with R.M. Nakamura on breast
cancer, B. Wahren (the co-editor) with P. Perlmann
on bladder cancer and so down through a list that
takes in skin, melanoma and central nervous
system; why it took 8 authors to write 9 pages
about prostatic cancer is unclear, they are a
veritable doctrine of doctors. I found the book
helpful and filled with a lot of good information
which with some cross-referencing provides an
appraisal of the state of the art in 1982. However,
as there has been a flood of tumour marker books
and conference reports on the market recently an
element of "deja vu" crept in from time to time as
I read some sections. Alas! This is the problem;
when so many publishing houses are in production,
the better books (and this is one) often get off to a
bad start with the readers fatigued by all that has
gone before. Nevertheless this book stands out
above the run of the mill, as a cornerstone for
research and practice in the 1980's.
E.H. Cooper,
Unit for Cancer Research,
School of Medicine,
Leeds.